Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nucana ( (NCNA) ) has shared an update.
NuCana on March 19, 2026 reported its fourth quarter and full-year 2025 results, highlighting clinical progress with its ProTide-based oncology pipeline and a strengthened balance sheet. The company said NUC-7738 showed encouraging safety and clinical activity in late-2025 Phase 2 NuTide:701 data in PD-1 inhibitor-resistant metastatic melanoma, and it aims to complete patient enrollment in the Phase 2 expansion and report final data in 2026 while seeking U.S. FDA regulatory guidance on a potential registrational path in melanoma.
Management also noted it is evaluating additional indications and combinations for NUC-7738 and refining development strategy for NUC-3373, supported by the appointment of a new chief operating officer to drive pipeline execution. NuCana ended 2025 with £24.3 million in cash and cash equivalents after May and July 2025 financings and warrant restructuring, and it expects this cash runway to fund planned operations into 2029 despite a wider 2025 net loss driven by non-cash warrant revaluation, professional fees, and higher share-based payment expenses.
The most recent analyst rating on (NCNA) stock is a Sell with a $2.50 price target. To see the full list of analyst forecasts on Nucana stock, see the NCNA Stock Forecast page.
Spark’s Take on NCNA Stock
According to Spark, TipRanks’ AI Analyst, NCNA is a Neutral.
The score is driven primarily by weak financial performance (no revenue, continued losses, and negative cash flow despite low leverage). Technicals add pressure with a bearish trend (below key moving averages and negative MACD). Valuation offers limited support due to a negative P/E and no dividend yield.
To see Spark’s full report on NCNA stock, click here.
More about Nucana
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, U.K., focused on improving cancer treatment outcomes using its proprietary ProTide technology to enhance nucleoside analog chemotherapy agents. Its pipeline includes lead anti-cancer candidates NUC-7738, which targets RNA polyadenylation and the tumor microenvironment, and NUC-3373, a targeted thymidylate synthase inhibitor being assessed in combinations for solid tumors and lung cancer.
Average Trading Volume: 62,981
Technical Sentiment Signal: Sell
Current Market Cap: $7.24M
See more insights into NCNA stock on TipRanks’ Stock Analysis page.